药物引起的错配修复缺陷：前景好坏参半

IF 48.8 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2025-06-12 DOI:10.1016/j.ccell.2025.05.004

Ye He, Hao-Xiang Wu, Feng Wang

{"title":"药物引起的错配修复缺陷：前景好坏参半","authors":"Ye He, Hao-Xiang Wu, Feng Wang","doi":"10.1016/j.ccell.2025.05.004","DOIUrl":null,"url":null,"abstract":"Most metastatic colorectal cancer (CRC) is mismatch repair proficient (pMMR) with low immunogenicity. In this issue of <em>Cancer Cell</em>, Vitiello et al. and Rousseau et al. reveal that temozolomide-cisplatin combinations induce mismatch repair-deficient-like phenotypes and reshape the tumor microenvironment in preclinical pMMR CRC models, yet the clinical trial calls for further optimization.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"8 1","pages":""},"PeriodicalIF":48.8000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Drug-induced mismatch repair deficiency: Mixed prospects\",\"authors\":\"Ye He, Hao-Xiang Wu, Feng Wang\",\"doi\":\"10.1016/j.ccell.2025.05.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Most metastatic colorectal cancer (CRC) is mismatch repair proficient (pMMR) with low immunogenicity. In this issue of <em>Cancer Cell</em>, Vitiello et al. and Rousseau et al. reveal that temozolomide-cisplatin combinations induce mismatch repair-deficient-like phenotypes and reshape the tumor microenvironment in preclinical pMMR CRC models, yet the clinical trial calls for further optimization.\",\"PeriodicalId\":9670,\"journal\":{\"name\":\"Cancer Cell\",\"volume\":\"8 1\",\"pages\":\"\"},\"PeriodicalIF\":48.8000,\"publicationDate\":\"2025-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Cell\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ccell.2025.05.004\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ccell.2025.05.004","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

大多数转移性结直肠癌（CRC）是错配修复精通（pMMR）低免疫原性。在本期的Cancer Cell中，Vitiello等和Rousseau等揭示了替莫唑胺-顺铂组合在临床前pMMR CRC模型中诱导错配修复缺陷样表型并重塑肿瘤微环境，但临床试验需要进一步优化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Drug-induced mismatch repair deficiency: Mixed prospects

Most metastatic colorectal cancer (CRC) is mismatch repair proficient (pMMR) with low immunogenicity. In this issue of Cancer Cell, Vitiello et al. and Rousseau et al. reveal that temozolomide-cisplatin combinations induce mismatch repair-deficient-like phenotypes and reshape the tumor microenvironment in preclinical pMMR CRC models, yet the clinical trial calls for further optimization.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.